Posted by Michael Wonder on 13 Oct 2023
US FDA approves Pfizer’s Velspity for adults with moderately to severely active ulcerative colitis
13 October 2023 - Approval of oral, once daily Velsipity based on favourable safety and efficacy data from the ELEVATE UC Phase 3 trials.
Pfizer announced today that the US FDA has approved Velsipity (etrasimod), an oral, once daily, selective sphingosine-1-phosphate receptor modulator for adults with moderately to severely active ulcerative colitis.
